Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With Schering-Plough, Merck Will Have Better Reach And Larger Product Basket In India

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - After a long spell of near-dormancy, in Dec. 2006, Schering-Plough's India unit roped in K.G. Ananthakrishnan from Pfizer India to head its fledgling arm with a mandate to revive the company
Advertisement

Related Content

Merck Unites With Schering Plough But India Goes Slow On Integration; Operational Structure And Merger Issues Remain Foggy
Merck Unites With Schering Plough But India Goes Slow On Integration; Operational Structure And Merger Issues Remain Foggy
Emerging Market Outlook: PharmAsia News Earnings Call Roundup
Emerging Market Outlook: PharmAsia News Earnings Call Roundup
Merck Vows To Be In Top Five In India By 2015; Push Will Come From 13 New Launches In The Next Two Years
Merck Vows To Be In Top Five In India By 2015; Push Will Come From 13 New Launches In The Next Two Years
Advertisement
UsernamePublicRestriction

Register

SC071023

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel